Spots Global Cancer Trial Database for A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Official Title: A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors
Study ID: NCT01928394
Conditions
Study Description
Brief Summary: To investigate the safety and efficacy of nivolumab as a single agent or in combination with ipilimumab in 6 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC), pancreatic adenocarcinoma (PC), small cell lung cancer (SCLC), bladder cancer (BC), and ovarian cancer (OC). A combination of nivolumab with ipilimumab and cobimetinib is also investigated in PC.
Detailed Description: All tumor types are now closed for enrollment: Triple Negative Breast Cancer Gastric Cancer Pancreatic Cancer Small Cell Lung Cancer Bladder Cancer Ovarian Cancer
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Local Institution - 0047, Muscle Shoals, Alabama, United States
Local Institution - 0044, Aurora, Colorado, United States
Local Institution - 0015, New Haven, Connecticut, United States
Local Institution - 0046, Gainesville, Florida, United States
Local Institution - 0021, Tampa, Florida, United States
Local Institution - 0001, Atlanta, Georgia, United States
Local Institution - 0004, Baltimore, Maryland, United States
Local Institution - 0005, Boston, Massachusetts, United States
Local Institution - 0043, Boston, Massachusetts, United States
Local Institution - 0049, Omaha, Nebraska, United States
Local Institution - 0045, Mineola, New York, United States
Local Institution - 0006, New York, New York, United States
Local Institution - 0003, Charlotte, North Carolina, United States
Local Institution - 0008, Durham, North Carolina, United States
Local Institution - 0007, Portland, Oregon, United States
Local Institution - 0011, Franklin, Tennessee, United States
Local Institution - 0002, Nashville, Tennessee, United States
Local Institution - 0009, Houston, Texas, United States
Local Institution - 0042, Seattle, Washington, United States
Local Institution - 0038, Toronto, Ontario, Canada
Local Institution - 0039, Copenhagen, , Denmark
Local Institution - 0014, Helsinki, Uusimaa, Finland
Local Institution - 0036, Tampere, , Finland
Local Institution - 0048, Bonn, , Germany
Local Institution - 0026, Frankfurt, , Germany
Local Institution - 0016, Heidelberg, , Germany
Local Institution - 0050, Kassel, , Germany
Local Institution - 0024, Bologna, , Italy
Local Institution - 0019, Milano, , Italy
Local Institution - 0020, Napoli, , Italy
Local Institution - 0032, Padova, , Italy
Local Institution - 0037, Barcelona, , Spain
Local Institution - 0023, Madrid, , Spain
Local Institution - 0017, Madrid, , Spain
Local Institution - 0010, Madrid, , Spain
Local Institution - 0018, London, Greater London, United Kingdom
Local Institution - 0012, Glasgow, Lanarkshire, United Kingdom
Local Institution - 0013, Sutton, Surrey, United Kingdom
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
